Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients
Information source: North Shore Long Island Jewish Health System
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiovascular Disease
Phase: N/A
Status: Completed
Sponsored by: North Shore Long Island Jewish Health System Official(s) and/or principal investigator(s): Suzanne El-Sayegh, MD, Principal Investigator, Affiliation: Staten Island University Hospital
Summary
The investigators are trying to find out if Clopidogrel (Plavix) is as effective in
hemodialysis patients as in patients not hemodialysed.
Clinical Details
Official title: Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Prevalence Of Plavix resistance
Secondary outcome: assess the risk factors for plavix resistance in the hemodialysis population
Detailed description:
Cardiovascular disease is very frequent in hemodialysis patients. Lot of hemodialysis
patients are on Clopidogrel (plavix). Their is some evidence that clopidogrel is not
effective in hemodialysis as it is effective in patient without kidney problem.
VerifyNow plavix is a machine that measure the ability of the blood to clot after giving
plavix.
We will collect blood from hemodialysis patients on plavix and check the ability of their
blood to clot and thus indirectly measuring the efficacy of Plavix.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All patients on hemodialysis taking Plavix
Exclusion Criteria:
- known to have bleeding disorder
- Severely anemic with hemoglobin level (Hb) < 10g/dl
- Low Platelets < 10000
Locations and Contacts
Staten Island University Hospital, Staten Island, New York 10305, United States
Additional Information
Starting date: June 2010
Last updated: May 30, 2013
|